abs314.txt	inhibition	of	androgen	biosynthesis	is	clinically	effective	for	treatingandrogen-responsive	prostate	cancer		abiraterone	a	clinical	first-in-classinhibitor	cytochrome	p450	17a1	(cyp17a1)	required	however	also	causes	hypertension	hypokalemia	and	edema	likely	duein	part	to	off-target	another	steroidogenic	cyp21a2	analogs	were	designed	based	on	structural	evidence	thatb-ring	substituents	may	favorably	interact	with	polar	residues	in	binding	cyp17a1and	sterically	clash	the	active	site	best	analogsincreased	selectivity	cyp17a1	up	84-fold	compared	6	6-foldfor	cocrystallization	validated	intended	newcontacts	docking	these	into	cyp21a2identified	steric	clashes	that	underlie	decreased	cyp21a2inhibition	overall	offer	advantage	form	ofreduced	side	effects
